-
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: New Orleans
-
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Lake Charles, Metairie, New Orleans
-
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Alexandria
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· Louisiana: Lafayette
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285 ·
Phase: Phase 3 ·
Ages: 8 Years to 18 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Bossier City, Eunice, Houma, Opelousas
-
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Metairie, Monroe
-
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Lake Charles
-
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Shreveport
-
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Monroe
-
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT07743450 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Baton Rouge, Metairie
-
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939 ·
Phase: Phase 3 ·
Ages: 12 Years to 17 Years ·
Sex: All (male and female)
· Louisiana: Lafayette
-
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
NCT07575932 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Mandeville, Prairieville
-
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Lake Charles
-
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
NCT07184086 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
NCT07477704 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Louisiana: Marrero
-
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252 ·
Phase: Phase 2 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· Louisiana: Shreveport
-
Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes
NCT05958368 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise
NCT06602141 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 45 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Body Composition Outcomes in MS Patients
NCT07530718 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Collaborative Multi-level Obesity Intervention Engaging Communities Trial
NCT06835686 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Louisiana: Avondale, Bastrop, Baton Rouge, Franklin
-
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
NCT07654361 ·
Phase: Phase 3 ·
Ages: 18 Years to 79 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
NCT07497880 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Louisiana: Kenner
-
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT07284979 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Shreveport
-
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Shreveport
-
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399 ·
Phase: Phase 3 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433 ·
Phase: Phase 3 ·
Ages: 45 Years to 99 Years ·
Sex: All (male and female)
· Louisiana: Covington, Marrero
-
Experimental Approach to Test Predictions of Body Weight Regulation Models
NCT06309576 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 40 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
NCT07684235 ·
Phase: Phase 3 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge, Marrero
-
GLP-1R Actions on Muscle and the Skeleton
NCT07154719 ·
Phase: Phase 4 ·
Ages: 18 Years to 50 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Impact of Lean Pork on Endothelial Function in Perimenopause
NCT06976112 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 40 Years to 55 Years ·
Sex: Female
· Louisiana: Baton Rouge
-
International Weight Control Registry
NCT04907396 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Iron Absorption in The Low Oxygen Exposure and Weight Status (LOWS) Study
NCT07542873 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years to 65 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Low Oxygen Exposure and Weight Status
NCT05289310 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years to 65 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459 ·
Phase: Phase 3 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge, Covington, Hammond, Mandeville
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086 ·
Phase: Phase 3 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Louisiana: New Iberia, Shreveport
-
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099 ·
Phase: Phase 3 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Louisiana: New Iberia, Shreveport
-
Pennington Generation Cohort
NCT06849206 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Phentermine's Impact on Treatment in Teens
NCT07282340 ·
Phase: Phase 2 ·
Ages: 12 Years to 17 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Predicting Appendicular Lean and Fat Mass With Bioelectrical Impedance Analysis Among Adult Patients With Obesity.
NCT06545435 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
NCT04228978 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Louisiana: New Orleans
-
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
NCT07446998 ·
Phase: Phase 2 ·
Ages: 65 Years to 100 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
NCT06116149 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· Louisiana: New Orleans
-
Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants
NCT07096011 ·
Phase: Not specified ·
Ages: 2 Weeks to 16 Weeks ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding
NCT04583514 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 42 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
The Dose Trial: Dose Intensity of Behavioral Interventions for Childhood Obesity
NCT06654323 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 5 Years to 17 Years ·
Sex: All (male and female)
· Louisiana: Baton Rouge
-
The Effects of Metabolic & Bariatric Surgery on Lipid Metabolism, Myeloid-Derived Suppressor Cells, and Cancer Cell Biology
NCT06059651 ·
Phase: Not specified ·
Ages: 35 Years to 60 Years ·
Sex: Female
· Louisiana: Baton Rouge